Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1-specific T cells and radiation in metastatic sarcoma
NCT02319824Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous NY-ESO-1-specific CD8-positive T lymphocytes in sarcoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
autologous NY-ESO-1-specific CD8-positive T lymphocytes
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT02319824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319824.